Reinhard Dummer

ZHAW Zurich University of Applied Sciences — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

151h-index126.8kcitations2.8kworks6.42yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(616), CAR-T cell therapy research(375), Cutaneous Melanoma Detection and Management(369), Cancer Immunotherapy and Biomarkers(349), Cutaneous lymphoproliferative disorders research(323)

Publications2.3k total

Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression

Molecular Cancer·2025Open Access

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma

Clinical Cancer Research·2025

Table 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Table 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Figure 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Figure 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Supplementary Data1 from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

2025Open Access

Suppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S10 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S13 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S12 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

page 1 of 114Next →

Frequent Co-authors

Dirk Schadendorf(23), Paolo A. Ascierto(14), Caroline Robert(13), James Larkin(11), Vanna Chiarion‐Sileni(11), Claus Garbe(11), Keith T. Flaherty(11), Piotr Rutkowski(10), F. Stephen Hodi(10), Axel Hauschild(10), Georgina V. Long(9), Jean‐Jacques Grob(8), Michele Maio(8), Brigitte Dréno(8), Jedd D. Wolchok(8), Célèste Lebbé(8), Carmen Loquai(8), Hugo Ten Cate(8), Michael Smylie(7), Jessica C. Hassel(7)